The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 801–900 of 1,003
Bleckmann, A., Conradi, L., Menck, K., Schmick, N. A., Schubert, A., Rietkötter, E., Arackal, J., Middel, P., Schambony, A., Liersch, T., et al. (2016) · Clinical and Experimental Metastasis · doi:10.1007/s10585-016-9780-3 · Cited by 38
Nordenskjöld, A. E., Fohlin, H., Fornander, T., Löfdahl, B., Skoog, L. K., & Stål, O. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4007-5 · Cited by 41
Jahny, E., Yang, H., Liu, B., Jahnke, B., Lademann, F., Knösel, T., Rümmele, P., Grützmann, R., Aust, D. E., Pilarsky, C. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170390 · Cited by 41
Pathway-based subnetworks enable cross-disease biomarker discovery
Haider, S. A., Yao, C. Q., Sabine, V. S., Grzadkowski, M. R., Stimper, V., Starmans, M. H. W., Wang, J., Nguyen, F., Moon, N. C., Lin, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07021-3 · Cited by 41
Prognostic value of serum alkaline phosphatase in spinal metastatic disease
Karhade, A. V., Thio, Q. C. B. S., Kuverji, M., Ogink, P. T., Ferrone, M. L., & Schwab, J. H. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0407-8 · Cited by 41
Darlix, A., Hirtz, C., Thézenas, S., Maceski, A. M., Gabelle, A., Lopez‐Crapez, E., de Forges, H., Firmin, N., Guiu, S., Jacot, W., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5287-z · Cited by 42
Lee, I., Lee, H., Hur, H., Kanda, M., Yook, J. H., Kim, B. S., Woo, Y., Kodera, Y., Kim, K., & Goel, A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3835 · Cited by 41
Prognostic biomarkers in ovarian cancer
Huang, J., Hu, W., & Sood, A. K. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0212 · Cited by 42
Maae, E., Olsen, D. A., Steffensen, K. D., Jakobsen, E. H., Brandslund, I., Sørensen, F. B., & Jakobsen, A. K. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1957-0 · Cited by 41
Abdel-Fatah, T. M. A., Arora, A., Alsubhi, N. H., Agarwal, D., Moseley, P. M., Perry, C., Doherty, R. E., Chan, S. Y. T., Green, A. R., Rakha, E. A., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.009 · Cited by 40
miRNA as markers for the diagnostic screening of colon cancer
Ahmed, F. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.869479 · Cited by 41
Kormelink, T. G., Powe, D. G., Kuijpers, S. A., Abudukelimu, A., Fens, M. H. A. M., Pieters, E. H. E., der Ven, W. W. K.-V., Habashy, H. O., Ellis, I. O., Blokhuis, B. R. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1868 · Cited by 42
Bodelón, C., Polley, M. Y., Kemp, T. J., Pesatori, A. C., McShane, L. M., Caporaso, N. E., Hildesheim, A., Pinto, L. A., & Landi, M. T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt175 · Cited by 40
Self-citationSurvivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
Werner, T. A., Tamkan-Ölcek, Y., Dizdar, L., Riemer, J. C., Wolf, A., Cupisti, K., Verde, P. E., Knoefel, W. T., & Krieg, A. H. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.5 · Cited by 40
Lin, J. S., Webber, E. M., Senger, C. A., Holmes, R. S., & Whitlock, E. P. (2011) · PubMed · Cited by 40
Liu, T., Chen, J., Shang, C., Shen, H., Huang, J., Liang, Y., Wang, W., Zhao, Y., Liu, D., Shu, M., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0445-5 · Cited by 40
Friese, K., Kost, B., Vattai, A., Marmé, F., Kühn, C., Mahner, S., Dannecker, C., Jeschke, U., & Heublein, S. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2510-7 · Cited by 40
CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma
Werner, T. A., Förster, C., Dizdar, L., Verde, P. E., Raba, K., Schott, M., Knoefel, W. T., & Krieg, A. H. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.364 · Cited by 40
Gaussian Mixture Models for Probabilistic Classification of Breast Cancer
Prabakaran, I., Wu, Z., Lee, C.-G., Tong, B., Steeman, S. L., Koo, G., Zhang, P. J., & Guvakova, M. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0573 · Cited by 40
Burum‐Auensen, E., DeAngelis, P. M., Schjolberg, A., Røislien, J., Mjåland, O., & Clausen, O. P. F. (2008) · Cell Proliferation · doi:10.1111/j.1365-2184.2008.00539.x · Cited by 40
Smith, E., Rubenstein, L. M., Ritchie, J. M., Lee, J. H., Haugen, T. H., Hamšíková, E., & Turek, L. P. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0054 · Cited by 40
APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma
Kosumi, K., Baba, Y., Ishimoto, T., Harada, K., Nakamura, K., Ohuchi, M., Kiyozumi, Y., Izumi, D., Tokunaga, R., Taki, K., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0739-7 · Cited by 39
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 47
Refining Prognosis in Lung Cancer
Mahar, A. L., Compton, C. C., McShane, L. M., Halabi, S., Asamura, H., Rami–Porta, R., & Groome, P. A. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000652 · Cited by 40
Self-citationGalván, J. A., Astudillo, A., Vallina, A., Crespo, G., Folgueras, M., & González, M. V. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-855 · Cited by 39
EGFR expression in advanced head and neck cutaneous squamous cell carcinoma
Sweeny, L., Dean, N. R., Magnuson, J. S., Carroll, W. R., Helman, E. E., Hyde, S. O., Desmond, R. L., & Rosenthal, E. L. (2011) · Head & Neck · doi:10.1002/hed.21802 · Cited by 39
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Okines, A. F. C., de Castro, D. G., Cunningham, D., Chau, I., Langley, R. E., Thompson, L. C., Stenning, S. P., Saffery, C., Barbáchano, Y., Coxon, F. Y., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.007 · Cited by 39
Design of Tumor Biomarker–Monitoring Trials: A Proposal by the European Group on Tumor Markers
Sölétormos, G., Duffy, M. J., Hayes, D. F., Sturgeon, C. M., Barak, V., Bossuyt, P. M., Diamandis, E. P., Gion, M., Hyltoft-Petersen, P., Lamerz, R., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.180778 · Cited by 39
Self-citationSekula, P., Mallett, S., Altman, D. G., & Sauerbrei, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178531 · Cited by 38
Self-citationMackie, F. L., Hall, M. J., Morris, R. K., & Kilby, M. D. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.05.008 · Cited by 41
Hamester, F., Legler, K., Wichert, B., Kelle, N., Eylmann, K., Roßberg, M., Ding, Y., Kuerti, S., Schmalfeldt, B., Milde‐Langosch, K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0607-2 · Cited by 39
Miller, H. A., Yin, X., Smith, S. A., Hu, X., Zhang, X., Yan, J., Miller, D. M., van Berkel, V. H., & Frieboes, H. B. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.012 · Cited by 39
Gallo, V., Egger, M., McCormack, V., Farmer, P. B., Ioannidis, J. P. A., Kirsch‐Volders, M., Matullo, G., Phillips, D. H., Schoket, B., Strömberg, U., et al. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9622-1 · Cited by 41
Wu, Y., & Cook, R. J. (2015) · Biometrics · doi:10.1111/biom.12302 · Cited by 38
p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas
Moreno-Galindo, C., Hermsen, M. A. J. A., Garcia-Pedrero, J. M., Fresno, M., Suarez, C. M., & Rodrigo, J. P. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.10.018 · Cited by 38
Werner, H. M. J., Trovik, J., Halle, M. K., Wik, E., Akslen, L. A., Birkeland, E., Bredholt, T., Tangen, I. L., Krakstad, C., & Salvesen, H. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090141 · Cited by 38
Heikkinen, T., Korpela, T., Fagerholm, R., Khan, S., Aittomäki, K., Heikkilä, P., BLOMQVIST, C. P., Carpén, O., & Nevanlinna, H. A. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2671-2 · Cited by 37
Too many numbers: Microarrays in clinical cancer research
Keating, P., & Cambrosio, A. (2011) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2011.10.004 · Cited by 39
Nam, S., Chang, H. R., Jung, H. R., Gim, Y., Kim, N. Y., Grailhe, R., Seo, H. R., Park, H. S., Balch, C., Lee, J., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.038 · Cited by 38
Chen, I. M., Raymond, V. M., Geis, J. A., Collisson, E. A., Jensen, B. V., Hermann, K. L., Erlander, M. G., Tempero, M. A., & Johansen, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.22080 · Cited by 38
Salmasi, A., SAID, J. W., Shindel, A. W., Khoshnoodi, P., Felker, E. R., Sisk, A. E. J., Grogan, T., McCullough, D., Bennett, J. P., Bailey, H., et al. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.03.004 · Cited by 38
Slik, K., Turkki, R., Carpén, O., Kurki, S. H., Korkeila, E. A., Sundström, J. T. T., & Pellinen, T. S. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001356 · Cited by 39
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence
Pruessmann, W., Rytlewski, J. A., Wilmott, J. S., Mihm, M. C., Attrill, G. H., Dyring‐Andersen, B., Fields, P., Zhan, Q., Colebatch, A. J., Ferguson, P. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0019-5 · Cited by 38
Nissen, N. I., Johansen, A. Z., Chen, I. M., Johansen, J. S., Pedersen, R. S., Hansen, C. P., Karsdal, M. A., & Willumsen, N. (2022) · Cancers · doi:10.3390/cancers14030819 · Cited by 41
Duchemann, B., Naigeon, M., Auclin, É., Ferrara, R., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Desnoyer, A., Danlos, F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004012 · Cited by 42
Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma
Oba, J., Nakahara, T., Hayashida, S., Makiko, K. I. D. O., Xie, L., Takahara, M., Uchi, H., Miyazaki, S., Abe, T., Hagihara, A., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.10.019 · Cited by 38
Querzoli, P., Coradini, D., Pedriali, M., Boracchi, P., Ambrogi, F., Raimondi, E., Sorda, R. L., Lattanzio, R., Rinaldi, R., Lunardi, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605991 · Cited by 38
Betts, G. N. J., Eustace, A., Patiar, S., Valentine, H. R., Irlam, J. J., Ramachandran, A., Merve, A., Homer, J. J., Möller‐Levet, C. S., Buffa, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.028 · Cited by 38
Li, M., Chen, K., Liu, F., Su, F., Li, S., & Zhu, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183448 · Cited by 38
Chapter 12: Systematic Review of Prognostic Tests
Rector, T. S., Taylor, B. C., & Wilt, T. J. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1899-y · Cited by 37
Bullock, M. D., Pickard, K. M., Mitter, R., Sayan, E., Primrose, J. M., Ivan, C., Călin, G. A., Thomas, G. J., Packham, G., & Mirnezami, A. H. (2015) · Oncotarget · doi:10.18632/oncotarget.3225 · Cited by 38
Andres, S. A., Edwards, A. B., & Wittliff, J. L. (2012) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21488 · Cited by 37
Giudice, A. D., D'Amico, D., Sobesky, J., & Wellwood, I. (2014) · Cerebrovascular Diseases · doi:10.1159/000360754 · Cited by 37
Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients
Lin, Y., Yin, W., Yan, T., Zhou, L., Di, G., Wu, J., Shen, Z., Shao, Z., & Lu, J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-342 · Cited by 37
Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer
Chen, Z., Gerhold‐Ay, A., Gebhard, S., Boehm, D. U., Solbach, C., Lebrecht, A., Battista, M. J., Sicking, I., Cotarelo, C., Cadenas, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044741 · Cited by 37
Pasquali, S., van der Ploeg, A. P. T., D, S. M. M., Stretch, J. R., Thompson, J. F., & Scolyer, R. A. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12064 · Cited by 37
Xu, J., Wan, X., Huang, X.-F., Chan, K. C. A., Hong, M., Wang, L., Long, Z., Liu, Q., Yan, M., Lo, Y. M. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6552 · Cited by 37
Ren, X., Zhou, G., Jiang, W., Sun, Y. H., Xu, Y.-F., Li, Y.-Q., Tang, X.-R., Wen, X., He, Q.-M., Yang, X.-J., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0369 · Cited by 37
Pitfalls in outcome prediction of breast cancer
Rakha, E. A. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201083 · Cited by 37
CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer
Stanisavljević, L., Aßmus, J., Storli, K. E., Leh, S. M., Dahl, O., & Myklebust, M. P. (2015) · Tumor Biology · doi:10.1007/s13277-015-4591-8 · Cited by 37
Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement
Janssens, A. C. J. W., Ioannidis, J. P. A., van Duijn, C. M., Little, J., & Khoury, M. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.02.004 · Cited by 37
Creemers, A., Ebbing, E. A., Pelgrim, T. C., Lagarde, S. M., van Etten‐Jamaludin, F. S., Henegouwen, M. I. V. B., Hulshof, M. C. C. M., Krishnadath, K. K., Meijer, S. L., Bijlsma, M. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31548-6 · Cited by 37
Li, P., Gao, Q., Jiang, X., Zhan, Z., Yan, Q., Li, Z., & Huang, C. (2018) · Journal of Cancer · doi:10.7150/jca.26947 · Cited by 37
Targeted mutation detection in breast cancer using MammaSeq™
Smith, N. G., Gyanchandani, R., Shah, O. S., Gurda, G. T., Lucas, P. C., Hartmaier, R. J., Brufsky, A., Puhalla, S., Bahreini, A., Kota, K. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1102-7 · Cited by 36
Swain, S. M., Tang, G., Lucas, P. C., Robidoux, A., Goerlitz, D. S., Harris, B. T., Bandos, H., Geyer, C. E., Rastogi, P., Mamounas, E. P., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05398-3 · Cited by 37
Popat, S., Zhao, D., Chen, Z., Pan, H., Shao, Y., Chandler, I. P., & Houlston, R. S. (2007) · PubMed · Cited by 37
Kassem, L. M. H., Deygas, M., Fattet, L., Lopez, J., Goulvent, T., Lavergne, E., Chabaud, S., Carrabin, N., Chopin, N., Bachelot, T., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1471-y · Cited by 37
Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock, Z. K., Hatoum, H. A., Musallam, K. M., Awada, A. H., & Shamseddine, A. I. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.008 · Cited by 37
Bouchalová, K., Svoboda, M., Kharaishvili, G., Vrbková, J., Bouchal, J., Trojanec, R., Koudeláková, V., Radová, L., Cwiertka, K., Hajdúch, M., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3061-7 · Cited by 37
Skliris, G. P., Hubé, F., Gheorghiu, I., Mutawe, M. M., Penner, C., Watson, P. H., Murphy, L. C., Leygue, E., & Myal, Y. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02955.x · Cited by 37
Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients
Kumar, M., Srivastava, G., Kaur, J., Assi, J. S., Alyass, A., Leong, I., MacMillan, C., Witterick, I., Shukla, N. K., Thakar, A., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0369-9 · Cited by 37
Pantel, A. R., & Mankoff, D. A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.008 · Cited by 37
Tang, Q., Holland‐Letz, T., Slynko, A., Ćuk, K., Marmé, F., Schott, S., Heil, J., Qu, B., Golatta, M., Bewerunge‐Hudler, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11640 · Cited by 36
Glass, A. G., Leo, M. C., Haddad, Z., Yousefi, K., du Plessis, M., Chen, C., Choeurng, V., Abdollah, F., Robbins, B. A., Ra, S., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.11.044 · Cited by 36
NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma
Arora, R. K., Haynes, L., Kumar, M., McNeil, R., Ashkani, J., Nakoneshny, S. C., Matthews, T. W., Chandarana, S. P., Hart, R. D., Jones, S. J. M., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-022-00578-8 · Cited by 37
Gustbée, E., Tryggvadottir, H., Markkula, A., Simonsson, M., Nodin, B., Jirström, K., Rose, C., Ingvar, C., Borgquist, S., & Jernström, H. (2015) · BMC Clinical Pathology · doi:10.1186/s12907-015-0008-2 · Cited by 36
An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer
Li, H. Z., Duhachek-Muggy, S., Qi, Y., Hong, Y., Behbod, F., & Żółkiewska, A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2220-4 · Cited by 36
Díaz-Padilla, I., Amir, E., Marsh, S., Liu, G., & MacKay, H. J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.034 · Cited by 36
Sawayama, H., Ishimoto, T., Watanabe, M., Yoshida, N., Baba, Y., Sugihara, H., Izumi, D., Kurashige, J., & Baba, H. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3371-1 · Cited by 36
Seibold, P., Hall, P. N., Schoof, N., Nevanlinna, H. A., Heikkinen, T., Benner, A., Liu, J., Schmezer, P., Popanda, O., Flesch‐Janys, D., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.02.008 · Cited by 36
Calpastatin is associated with lymphovascular invasion in breast cancer
Storr, S. J., Mohammed, R. A., Woolston, C. M., Green, A. R., Parr, T., Spiteri, I., Caldas, C., Ball, G., Ellis, I. O., & Martin, S. G. (2011) · The Breast · doi:10.1016/j.breast.2011.04.002 · Cited by 36
Karamitopoulou, E., Zlobec, I., Gloor, B., Kondi-Pafiti, A. I., Lugli, A., & Perren, A. A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-311 · Cited by 36
CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma
Werner, T. A., Förster, C., Dizdar, L., Verde, P. E., Raba, K., Schott, M., Knoefel, W. T., & Krieg, A. H. (2018) · Journal of Cancer · doi:10.7150/jca.23042 · Cited by 36
Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?
Helsmoortel, H. H., Everaert, C., Lumen, N., Ost, P., & Vandesompele, J. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.05.001 · Cited by 36
A genome‐wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells
Arfaoui, A., Rioualen, C., Azzoni, V., Pinna, G., Finetti, P., Wicinski, J., Josselin, E., Macario, M., Castellano, R., Léonard-Stumpf, C., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809930 · Cited by 39
DNA methylation markers predict recurrence-free interval in triple-negative breast cancer
Fackler, M. J., Cho, S., Cope, L., Gabrielson, E. W., Visvanathan, K., Wilsbach, K., Meir-Levi, D., Lynch, C. F., Marks, J. R., Geradts, J., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0145-3 · Cited by 36
Prognostic Research in Traumatic Brain Injury: Markers, Modeling, and Methodological Principles
Helmrich, I. R., Lingsma, H. F., Turgeon, A. F., Yamal, J., & Steyerberg, E. W. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2019.6708 · Cited by 36
Ribbat‐Idel, J., Perner, S., Kuppler, P., Klapper, L., Krupar, R., Watermann, C., Paulsen, F., Offermann, A., Bruchhage, K., Wollenberg, B., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.622330 · Cited by 36
Liu, J., Li, Y., Li, Q., Liang, D., Wang, Q., & Liu, Q. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06128-4 · Cited by 36
Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics
Balkenhol, M. C. A., Ciompi, F., Świderska-Chadaj, Ż., van de Loo, R., Intezar, M., Otte‐Höller, I., Geijs, D. J., Lotz, J., Weiss, N., de Bel, T., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.02.007 · Cited by 36
Levidou, G., El-Habr, E. A., Saetta, A. A., Bamias, C., Katsougiannis, K., Patsouris, E., & Korkolopoulou, P. A. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0204-y · Cited by 36
Fountzilas, G., Christodoulou, C., Bobos, M., Kotoula, V., Eleftheraki, A. G., Xanthakis, I., Batistatou, A. K., Pentheroudakis, G. E., Xiros, N., Papaspirou, I., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-212 · Cited by 36
Messer, B., Griffiths, J., & Baudouin, S. (2011) · QJM · doi:10.1093/qjmed/hcr210 · Cited by 36
Mebarki, S., Désert, R., Sulpice, L., Sicard, M., Desille, M., Canal, F., Dubois‐Pot‐Schneider, H., Bergeat, D., Turlin, B., Bellaud, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9346 · Cited by 39
Pfitzner, B. M., Lederer, B., Lindner, J., Solbach, C., Engels, K., Rezai, M., Dohnal, K., Tesch, H., Hansmann, M. L., Salat, C., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.171 · Cited by 36
Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
Wallerek, S., & Sørensen, J. B. (2015) · European Respiratory Review · doi:10.1183/16000617.00005814 · Cited by 35
Schultz, N. A., Christensen, I. J., Werner, J., Giese, N. A., Jensen, B. V., Larsen, O. F., Bjerregaard, J. K., Pfeiffer, P., Calatayud, D., Nielsen, S. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067059 · Cited by 38
Melanoma Biomolecules: Independently Identified but Functionally Intertwined
Dye, D. E., Medic, S., Ziman, M. R., & Coombe, D. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00252 · Cited by 37
Papaxoinis, G., Kotoula, V., Alexopoulou, Z., Kalogeras, K. T., Zagouri, F., Timotheadou, E. T., Gogas, H. J., Pentheroudakis, G. E., Christodoulou, C., Koutras, A. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140293 · Cited by 35
Ye, M., Huang, T., Ying, Y., Li, J., Yang, P., Ni, C., Zhou, C., & Chen, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13992 · Cited by 35
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
